Understanding the molecular basis of stochastic bi-stable obesity

Projektinformationen

EPOC

ID Finanzhilfevereinbarung: 707123

DOI

10.3030/707123

Projekt abgeschlossen

EK-Unterschriftsdatum 21 April 2016

Startdatum 1 Dezember 2016

Enddatum 30 November 2018

Finanziert unter

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Gesamtkosten

€ 159 460,80

EU-Beitrag

€ 159 460,80

Koordiniert durch

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
Germany

Periodic Reporting for period 1 - EPOC (Understanding the molecular basis of stochastic bi-stable obesity)

Berichtszeitraum: 2016-12-01 bis 2018-11-30

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Recent estimates place obesity incidence at more than 600 millions of people worldwide. The long-term implications of this disease include exacerbation of global heart disease, diabetes, and cancer, making obesity one of the world's chief socio-economic challenges of the next decade.
People are not all equal when it comes to emergence of obesity. Indeed, some populations seem protected, others seem prone to its development. Population level phenotypic variation, which describes the variability of a phenotype in a given population, is thought to serve as a mechanistic platform for adaptation and evolution. Phenotypic variation can be of genetic and/or epigenetic origin.
Whereas, the last decade has seen much progress in obesity genetics, our understanding of epigenetic regulation of the disease is poor.
Our lab recently published data about specific mutant mice developing an unprecedented bi-stable stochastic obesity phenotype. Approximately 20% of the genetically identical, littermate-controlled heterozygous mutant mice develop obesity while the remaining ~80% remain as lean as wild-type littermates, resulting in a bi-modal body weight distribution in the population. Here, we proposed to map the molecular basis of a chromatin state dependent epigenetic switch that to the best of our knowledge buffers metabolic programming, establishes phenotypic bi-stability and thereby generate a deeper understanding of the mechanisms underlying bi-stable obesity.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

During the period covered by the report, we established a high-dimensional phenome matrix based on the body weight and Fat/lean mass. This matrix served as a critical genetic reference point for understanding variation and stochasticity at the physiological and molecular levels. By using two mice models [Trim28D9/ and Nnat+/-p], we performed metabolic and neurologic phenotyping, and we also processed to RNA-sequencing and ChIP-sequencing on epididymal biopsy from phenotypic extremes.

In the same time, we began to set up a sufficient matrix for determination of high-confidence core molecular patterns specific to each model and to stochastic obesity in general. This matrix is based on in vivo analysis (indirect calorimetry during fed state) and ex vivo analysis (blood profile and adipocytes profile).

This study clearly demonstrated a new example of phenotypic co-variation with specific molecular mechanisms underlying this bi-stable obesity. We have still datas to analyze and experiments to perform before the publication step, but the results were presented in differents scientific meetings (TRIRHENA Chromatin club meeting, MPI-IE Institute Seminar, MPI-IE Epigenetics meeting).

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

We believe that switch-like developmental processes may underpin as much as 50% of pre-pubescent obesity with strong potential for life-long added risk for some of the most widespread modern diseases (diabetes, cardiovascular and neurological disease, and cancer). As indicated, the project has, in a preliminary sense, identified a second-ever polyphenism in the mouse and therefore demonstrates a novel dimension to the possible outcomes of mammalian epigenetic reprogramming. The greatest impact of this project therefore is a significantly deeper understanding of the epigenetic (re)programming in metabolic diseases. Based on this knowledge, our goal is to begin work towards identification of early epigenetic biomarkers to prediction the non-mendelian components of metabolic disease. Novel therapeutic and preventative strategies will naturally go hand in hand with such developments.